FURTHER READING

1. J Acquir Immune Defic Syndr 2002; 29(2): S2-9
   
   
2. J Acquir Immune Defic Syndr 2002; 29(2):
   S10-15
   
   
3. HIV Clin Trials 2002; 3(4): 371-78
   
   
4. AIDS 2000; 14: 357-66
   
   
5. Clin Infect Dis 1999; 29: 824-30
   
   
6. 7th Conference Retroviruses Op. Inf 2000, Abstract 73
   
   
7. Mannerheimer et al. 13th International AIDS Conference 2000; Abstract TuOrB421
   
   
8. Ann Intern Med 2001; 134: 968-77
   
   
9. J Acquir Immune Defic Syndr 1998; 18: 117-25
   
   
10. AIDS 2001; 15: 1367-77
    
    
11. Wenger et al. 6th Conference Retroviruses Op Inf, 1999; Abstract 98
    
    
12. Ann Intern Med 2000; 133: 21-30
    
    
13. Dezii et al. 5th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 2000
    
    
14. Bass and Smith. 14th World AIDS Conference, 2002; Abstract MoPeB3290
    
    
15. Moss et al. 6th International Congress on Drug Therapy in HIV Infection, 2002; Poster 105
    
    
16. Parruti et al. 6th International Congress on Drug Therapy in HIV Infection, 2002; Poster
    
    
17. Moyle et al. 6th International Congress on Drug Therapy in HIV Infection, 2002; Poster
    
    
18. Antiviral Therapy 2003; 6: 249-53
    
    
19. Landman et al. 9th Congress on Retroviruses and Opportunistic Infections 2002;
    Poster 458 W
    
    
20. Maggiolo et al. 42nd International Congress on Antimicrobial Agents and Chemotherapy 2002; Poster H-163
    
    
21. Keiser P, et al. 8th European Conference on Clinical Aspects and Treatment of HIV infection, 2001
    
    
22. Matthews et al. 1st International AIDS Society Conference on Opportunistic Infections and Treatment 2001
    
    
23. J Infect Dis 2002; 185: 1062-69
    
    
24. Phillips AN et al. 8th Conference on Retroviruses and Opportunistic Infections, 2001; Poster 324.
    
    
25. Arribas J et al. 11th European Conference of Clinical Microbiology and Infectious Diseases, 2001
    
    
26. AIDS 2001; 15: 547-51